Literature DB >> 22420970

Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma: a plausible approach? A single-institution experience in 10 patients.

Theodore Girinsky1, Amaury Paumier, Christophe Ferme, Colette Hanna, Vincent Ribrag, François Leroy-Ladurie, Mithra Ghalibafian.   

Abstract

PURPOSE: To propose an alternative approach for treatment of pulmonary marginal zone lymphoma, using a very small radiation dose (2 × 2 Gy) delivered exclusively to tumor sites. METHODS AND MATERIALS: Patients had localized pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma according to the World Health Organization classification. The 6-MV radiation treatments were delivered using tumor-limited fields, except in cases of diffuse bilateral involvement. Two daily fractions of 2 Gy were delivered to tumor-limited fields using a 6-MV linear accelerator.
RESULTS: Ten patients with pulmonary MALT lymphoma entered the study. All but 1 had localized tumor masses. The median follow-up was 56 months (range, 2-103 months). Complete remission or an unconfirmed complete remission was obtained in 60% of patients within the first 2 months, and two additional partial responses were converted into a long-term unconfirmed complete remission. All patients are well and alive, no local progression was observed, and the 5-year progression-free survival rate was 87.5% (95% confidence interval 49%-97%).
CONCLUSIONS: Our results suggest that extremely low radiation doses delivered exclusively to tumor sites might be a treatment option in pulmonary MALT lymphoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22420970     DOI: 10.1016/j.ijrobp.2012.01.005

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Watch-and-wait or immediate immunotherapy/immunochemotherapy in patients with phase IE primary pulmonary MALT lymphoma? A multicenter retrospective study.

Authors:  Wei Yan; Bin Wu; Ai-Jun Liao; Wei Yang; Hui-Han Wang
Journal:  Ann Hematol       Date:  2021-01-22       Impact factor: 3.673

2.  Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas.

Authors:  Marzia Cerrato; Erika Orlandi; Angelisa Vella; Sara Bartoncini; Giuseppe C Iorio; Diego Bongiovanni; Francesco Capriotti; Carola Boccomini; Francesco Vassallo; Chiara Cavallin; Viola De Luca; Francesca R Giglioli; Umberto Ricardi; Mario Levis
Journal:  Br J Radiol       Date:  2021-06-16       Impact factor: 3.039

3.  Clinical manifestations of pulmonary mucosa-associated lymphoid tissue lymphoma: single-center experience with 18 patients.

Authors:  Shasha Zhao; Lin Zhang; Zhenyang Gu; Chengying Zhu; Shu Fang; Nan Yang; Feiyan Wang; Lixun Guan; Lan Luo; Chunji Gao
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

4.  Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.

Authors:  Khalil Saleh; Jean-Marie Michot; Antoine Schernberg; Julien Lazarovici; Claude Chahine; Alina Danu; Nadine Khalife-Saleh; Julien Rossignol; David Ghez; Valentine Martin; Renaud Mazeron; Christophe Fermé; Angela Boros; Vincent Ribrag; Theodore Girinsky
Journal:  Cancer Med       Date:  2020-04-06       Impact factor: 4.452

5.  Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma.

Authors:  Jong Yun Baek; Do Hoon Lim; Dongryul Oh; Heerim Nam; Jae J Kim; Jun Haeng Lee; Byung-Hoon Min; Hyuk Lee
Journal:  Cancer Res Treat       Date:  2021-04-01       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.